{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:20:31Z","timestamp":1791379231528,"version":"4.3.2"},"reference-count":59,"publisher":"MedWorks Media","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Purpose of Review\nOpioid medications are a pillar of acute and chronic analgesia, though their use is often accompanied by side-effects, such as opioid-induced constipation. Unfortunately, tolerance rarely develops to this untoward side effect. This review presents the background, evidence, and indications for the use of Naldemedine (Brand name Symproic 0.2 mg tablets) to treat opioid-induced constipation.\nRecent Findings\nOpioids are often used for the treatment of acute and chronic analgesia. Outside of the central effect they exert, they also interact with peripheral receptors, resulting in opioid-induced constipation, the commonest of side effects of chronic opioid usage. Complications include colonic distention, ileus, perforation, and can progress to other serious bowel complications, which can result in hospitalization and fatal events.\nFor the most part, laxatives and other anti-constipation therapies are often inefficient and require intervention directed at the root cause, such as peripheral mu receptor agonists, including methylnaltrexone, naloxegol, and naldemedine. Naldemedine is the most recent to gain FDA approval of the group.\nAn antagonist of Mu, Kappa, and Delta peripheral receptors, Naldemedine, is the only drug to counteract all three receptor classes. It was shown to be both safe and effective when compared with placebo. No data exists to compare its efficacy to that of other members of the group.\nSummary\nOpioids are frequently used in the management of acute and chronic pain. The most common of the side effects is opioid-induced constipation, secondary to the peripheral activity of opioids. Naldemedine is an FDA-approved, once-daily oral tablet that counteracts this side effect by antagonizing mu, kappa, and delta-opioid receptors and has been shown to be safe and effective. Further investigation including head-to-head clinical trials are required to evaluate the relative efficacy of naldemedine compare with other peripheral opiate receptor antagonists.<\/jats:p>","DOI":"10.64719\/pb.4616","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:23:34Z","timestamp":1761045814000},"page":"97-118","source":"Crossref","is-referenced-by-count":2,"title":["Naldemedine for the Use of Management of Opioid Induced Constipation"],"prefix":"10.64719","volume":"50","author":[{"given":"Ivan","family":"Urits","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley Cornwall","family":"Kiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conner Joseph","family":"Clay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"Monteferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai Won","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amnon A.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Hasoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Bingham R, Lloyd-Thomas AR, Sury MRJ. Hatch and Sumner\u2019s textbook of paediatric anaesthesia. 2008:786. Hodder Arnold.","DOI":"10.1201\/b13331"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Wang SC, Chen YC, Lee CH, Cheng CM. Opioid addiction, genetic susceptibility, and medical treatments: A review. International Journal of Molecular Sciences. 2019;20 Vol. MDPI AG.","DOI":"10.3390\/ijms20174294"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Floret N, Viel JF, Mauny F, Hoen B, Piarroux R. Negligible risk for epidemics after geophysical disasters. 2006;12:543\u2013548. Vol. Emerging Infectious Diseases. Centers for Disease Control and Prevention (CDC)","DOI":"10.3201\/eid1204.051569"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Skolnick P. The Opioid Epidemic: Crisis and Solutions. Annu Rev Pharmacol Toxicol Annu Rev Pharmacol Toxicol. 2018;58:143\u2013159.","DOI":"10.1146\/annurev-pharmtox-010617-052534"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Sharma B, Bruner A, Barnett G, Fishman M. Opioid Use Disorders. Child Adolesc Psychiatr Clin N Am. 2016;25(3):473\u2013487.","DOI":"10.1016\/j.chc.2016.03.002"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Califf RM, Woodcock J, Ostroff S. A proactive response to prescription opioid abuse. New England Journal of Medicine. 2016;374:1480\u20131485. Vol. Massachussetts Medical Society.","DOI":"10.1056\/NEJMsr1601307"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Schuchat A, Houry D, Guy GP. New data on opioid use and prescribing in the United States. American Medical Association. 2017;318:425\u2013426. Vol. JAMA \u2014 Journal of the American Medical Association.","DOI":"10.1001\/jama.2017.8913"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Bao Y, Pan Y, Taylor A, Radakrishnan S, Luo F, Pincus HA et al. Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. Health Aff. 2016;35(6):1045\u20131051.","DOI":"10.1377\/hlthaff.2015.1673"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Brock C, Olesen SS, Olesen AE, Fr\u00f8kjaer JB, Andresen T, Drewes AM. Opioid-induced bowel dysfunction: Pathophysiology and management. Drugs. 2012;72:1847\u20131865. Vol.","DOI":"10.2165\/11634970-000000000-00000"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Holzer P. Pharmacology of Opioids and their Effects on Gastrointestinal Function. 2014","DOI":"10.1038\/ajgsup.2014.4"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Sternini C, Patierno S, Selmer I-S, Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil. 2004;16(s2):3\u201316.","DOI":"10.1111\/j.1743-3150.2004.00553.x"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther. 2012;50(5):360\u2013367.","DOI":"10.5414\/CP201646"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Sharma SK, Nirenberg M, Klee WA. Morphine receptors as regulators of adenylate cyclase activity. Proc Natl Acad Sci U S A. 1975;72(2):590\u2013594.","DOI":"10.1073\/pnas.72.2.590"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterology and Motility. 2004;16:17\u201328. Vol.","DOI":"10.1111\/j.1743-3150.2004.00554.x"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Drewes AM, Munkholm P, Simr\u00e9n M, Breivik H, Kongsgaard UE, Hatlebakk JG et al. Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group. 2016;11:111\u2013122. Vol. Scandinavian Journal of Pain. Elsevier B.V.","DOI":"10.1016\/j.sjpain.2015.12.005"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Gaertner J, Siemens W, Camilleri M, Davies A, Drossman DA, Webster LR et al. Definitions and outcome measures of clinical trials regarding opioid-induced constipation: A systematic review. Journal of Clinical Gastroenterology. 2015;49:9\u201316. Vol. Lippincott Williams and Wilkins.","DOI":"10.1097\/MCG.0000000000000246"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Webster LR. Opioid-Induced Constipation. Pain Med (United States) 2015;16:S16\u201321.","DOI":"10.1111\/pme.12911"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic noncancer pain. Neurogastroenterol Motil. 2010;22(4)","DOI":"10.1111\/j.1365-2982.2009.01458.x"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: Results of a U.S. and European patient survey (PROBE 1) Pain Med. 2009;10(1):35\u201342.","DOI":"10.1111\/j.1526-4637.2008.00495.x"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Sykes NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med. 1998;12(5):375\u2013382.","DOI":"10.1191\/026921698674125048"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K et al. Gastrointestinal side effects in chronic opioid users: Results from a population-based survey. Aliment Pharmacol Ther. 2008;27(12):1224\u20131232.","DOI":"10.1111\/j.1365-2036.2008.03689.x"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain \u2014 United States. [cited 2018 Jul 2];2016 Mar 18;65(1):1\u201349. MMWR Recomm Reports [Internet]. 2016. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26987082.","DOI":"10.15585\/mmwr.rr6501e1"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Panchal SJ, M\u00fcller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61(7):1181\u20131187.","DOI":"10.1111\/j.1742-1241.2007.01415.x"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Bowers BL, Crannage AJ. Journal of Pharmacy Practice. Vol. 32. SAGE Publications Inc; 2019. The Evolving Role of Long-Term Pharmacotherapy for Opioid-Induced Constipation in Patients Being Treated for Noncancer Pain; pp. 558\u2013567. Vol.","DOI":"10.1177\/0897190017745395"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Emmanuel A, Johnson M, McSkimming P, Dickerson S. Laxatives do not improve symptoms of opioid-induced constipation: Results of a patient survey. Pain Med (United States) 2017;18(10):1932\u20131940.","DOI":"10.1093\/pm\/pnw240"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Jamal MM, Adams AB, Jansen J-P, Webster LR. A Randomized, Placebo-Controlled Trial of Lubiprostone for Opioid-Induced Constipation in Chronic Noncancer Pain. Am J Gastroenterol. 2015;110(5):725\u2013732.","DOI":"10.1038\/ajg.2015.106"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Cryer B, Katz S, Vallejo R, Popescu A, Ueno R. A Randomized Study of Lubiprostone for Opioid-Induced Constipation in Patients with Chronic Noncancer Pain. Pain Med. 2014;15(11):1825\u20131834.","DOI":"10.1111\/pme.12437"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Spierings ELH, Rauck R, Brewer R, Marcuard S, Vallejo R. Long-Term Safety and Efficacy of Lubiprostone in Opioid-induced Constipation in Patients with Chronic Noncancer Pain. Pain Pract. 2016;16(8):985\u2013993.","DOI":"10.1111\/papr.12347"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Murphy JA, Sheridan EA. Vol. 52. SAGE Publications Inc; 2018. Evidence Based Review of Pharmacotherapy for Opioid-Induced Constipation in Noncancer Pain; pp. 370\u2013379. Vol. Annals of Pharmacotherapy.","DOI":"10.1177\/1060028017739637"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Iyer SS, Randazzo BP, Tzanis EL, Schulman SL, Zhang H, Wang W et al. Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms. Value Heal. 2011;14(1):177\u2013183.","DOI":"10.1016\/j.jval.2010.11.003"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Michna E, Blonsky ER, Schulman S, Tzanis E, Manley A, Zhang H et al. Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Patients With Chronic, Nonmalignant Pain: A Randomized Controlled Study. J Pain. 2011;12(5):554\u2013562.","DOI":"10.1016\/j.jpain.2010.11.008"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Rauck R, Slatkin NE, Stambler N, Harper JR, Israel RJ. Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain. Pain Pract. 2017;17(6):820\u2013828.","DOI":"10.1111\/papr.12535"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387\u20132396.","DOI":"10.1056\/NEJMoa1310246"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Webster L, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain. 2013;154(9):1542\u20131550.","DOI":"10.1016\/j.pain.2013.04.024"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Webster L, Chey WD, Tack J, Lappalainen J, Diva U, Sostek M. Randomised clinical trial: The longterm safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther. 2014;40(7):771\u2013779.","DOI":"10.1111\/apt.12899"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Luthra P, Burr NE, Brenner DM, Ford AC. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: Systematic review and network meta-analysis. Gut. 2019;68(3):434\u2013444.","DOI":"10.1136\/gutjnl-2018-316001"},{"key":"ref37","unstructured":"Drug Enforcement Administration Department of Justice. Schedules of controlled substances: removal of naloxegol from control. Final rule. Fed Regist. 2015;80(15):3468\u20133470."},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN, Mawe GM. Vol. 26. Blackwell Publishing Ltd; 2014. Emerging treatments in neurogastroenterology: A multidisciplinary working group consensus statement on opioid-induced constipation; pp. 1386\u20131395. Vol. Neurogastroenterology, and motility.","DOI":"10.1111\/nmo.12417"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Kanemasa T, Koike K, Takase K, Arai T, Nakamura A, Morioka Y et al. Pharmacological Profile of Naldemedine, a Peripherally Acting \u03bc-Opioid Receptor Antagonist: Comparison with Naloxone and Naloxegol. J Pharmacol Exp Ther. 2020 jpet.119.264515.","DOI":"10.1124\/jpet.119.264515"},{"key":"ref40","unstructured":"Hu K, Bridgeman MB. Naldemedine (Symproic) for the treatment of opioid-induced constipation. 2018;43:601. Vol. P and T. Medi Media USA Inc."},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Watari R, Matsuda A, Ohnishi S, Hasegawa H. Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting \u03bc-opioid receptor antagonist. Drug Metab Pharmacokinet. 2019;34(2):126\u2013133.","DOI":"10.1016\/j.dmpk.2018.12.002"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Fukumura K, Yokota T, Baba Y, Arjona Ferreira JC. Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers. Clin Pharmacol Drug Dev. 2018;7(5):474\u2013483.","DOI":"10.1002\/cpdd.387"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Markham A. Naldemedine: First Global Approval. Drugs. 2017;77(8):923\u2013927.","DOI":"10.1007\/s40265-017-0750-0"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Ohnishi S, Fukumura K, Kubota R, Wajima T. Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. Xenobiotica. 2019;49(9):1044\u20131053.","DOI":"10.1080\/00498254.2018.1536815"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Fukumura K, Yamada T, Yokota T, Kawasaki A. The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine. Clin Pharmacol Drug Dev. 2020;9(2):162\u2013174.","DOI":"10.1002\/cpdd.690"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Webster L, Yamada T, Arjona FJ. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain. Pain Med. 2017;18(12):2350\u20132360.","DOI":"10.1093\/pm\/pnw325"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Katakami N, Oda K, Tauchi K, Nakata K, Shinozaki K, Yokota T et al. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer. J Clin Oncol. 2017;35(17):1921\u20131928.","DOI":"10.1200\/JCO.2016.70.8453"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Hale M, Wild J, Reddy J, Yamada T, Arjona Ferreira JC. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomized, parallel-group trials. Lancet Gastroenterol Hepatol. 2017;2(8):555\u2013564.","DOI":"10.1016\/S2468-1253(17)30105-X"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Webster LR, Nalamachu S, Morlion B, Reddy J, Baba Y, Yamada T et al. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain. 2018;159(5):987\u2013994.","DOI":"10.1097\/j.pain.0000000000001174"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T et al. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer. J Clin Oncol. 2017;35(34):3859\u20133866.","DOI":"10.1200\/JCO.2017.73.0853"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(6):1461\u20131467.","DOI":"10.1093\/annonc\/mdy118"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Saito Y, Yokota T, Arai M, Tada Y, Sumitani M. Naldemedine in japanese patients with opioid-induced constipation and chronic noncancer pain: Open-label phase III studies. J Pain Res. 2019;12:127\u2013138.","DOI":"10.2147\/JPR.S175900"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Wild J, Yamada T, Ferreira JCA, Hale M. Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: Results from 2 randomized, placebo-controlled, phase 3 trials. Pain. 2019;160(10):2358\u20132364.","DOI":"10.1097\/j.pain.0000000000001629"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Wild J, Webster L, Yamada T, Hale M. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients \u2265 65 Years of Age. Drugs and Aging. 2020;37(4):271\u2013279.","DOI":"10.1007\/s40266-020-00753-2"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Osaka I, Ishiki H, Yokota T, Tada Y, Sato H, Okamoto M et al. Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomized controlled studies. ESMO Open. 2019;4(4):527.","DOI":"10.1136\/esmoopen-2019-000527"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Esmadi M, Ahmad D, Hewlett A. View of Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation: A Meta-Analysis. J Gastrointest Liver Dis. 2019;28(1):41\u201346.","DOI":"10.15403\/jgld.2014.1121.281.any"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Takagi Y, Osawa G, Kato Y, Ikezawa E, Kobayashi C, Aruga E. Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: A retrospective cohort study. BMC Gastroenterol. 2020;20(1):25.","DOI":"10.1186\/s12876-020-1173-z"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Sato J, Tanaka R, Ishikawa H, Suzuki T, Shino M. A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting. Support Care Cancer. 2020;28(3):1083\u20131088.","DOI":"10.1007\/s00520-019-04884-0"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Sridharan K, Sivaramakrishnan G. Drugs for Treating Opioid-Induced Constipation: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials. J Pain Symptom Manage. 2018;55(2):468\u2013479.e1.","DOI":"10.1016\/j.jpainsymman.2017.08.022"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:35:59Z","timestamp":1791315359000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/naldemedine-for-the-use-of-management-of-opioid-induced-constipation\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":59,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4616","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}